There’s no doubt about it. We are living in a time of astounding financial opportunities.
Last year, was a great one year for the average retail investor, continuing the epic bull market that began in March 2009. As we move into 2020, it looks like it has the potential to keep right on going.
The terrific economy that we’ve had has helped propel stocks to record highs. Unemployment remains at 50-year lows as real income adjusted for inflation is moving up for millions of Americans.
In a case like this, you’d think all you have to do from here on out is just coast on autopilot. After all, the bellwether S&P 500 was up roughly 28.9% for the year as of the close on December 31.
But, as impressive as that sounds, you could do much better in 2020.
That’s because the S&P 500’s numbers for the year are nothing compared to the gains members of my monthly tech investing newsletter, the Nova-X Report, scored in 2019.
Indeed, our three best performers for the year more than doubled the S&P.
I’ve been writing about 5G high-speed cellular networks for more than five years now, and I couldn’t be more excited for what’s ahead in 2020.
Sure, 2019 saw a fair amount of progress in rolling out this advanced new platform. The nextgen mobile network is available in a few markets.
But we have a big catalyst coming in fall 2020. That’s when Apple Inc. (AAPL) unveils a new iPhone that’s 5G native.
Don’t underestimate the importance of this move. Apple sets the standard for the rest of the sector.
5G will be important for the entire tech ecosystem in the year ahead, and it’s just one major catalyst that investors should track. There are key developments with chip stocks and beaten-down software and cloud players that all matter to your portfolio.
Without semiconductors, there is no American economy. That’s because the American economy is driven by tech, and tech is driven by semiconductors. After an outstanding jobs report, big media is finally coming around to my point of view that tech investors have lot of upside ahead, and very few reasons to be worried. In times like these, it’s important to look for the pick-and-shovel plays that will be supporting development in as many breakout sectors as possible. The right semiconductor plays will be able to profit from the rollout of 5g wireless, along with advances such as cobots, robots that cooperate with humans in the workplace. With new breakouts just around the corner in 2020, you’re not going to want to miss the firms that will be holding it all together. Click here to watch.
I’ll never forget sailing with my buddies on San Francisco Bay back in the summer of 2016.
Both are high-tech investors who were absolutely convinced that Donald J. Trump had exactly zero chance of becoming president.
But I strongly disagreed. That’s because I follow these things closely since big political elections can affect the stock market, not to mention every sector of the economy, including high tech.
On top of all that, I was a young auto analyst in Detroit back in 1980 when Ronald Reagan was elected. I personally talked with union members who crossed party lines and helped put Reagan in the White House.
I told my sailing buddies that the same dynamic was at work in 2016. I didn’t just predict that Trump would win, I walked them through several of the key districts and showed them exactly how he would do it.
Here I go again…I believe that Trump now has a much better chance of getting reelected than he did before the Democratic-led impeachment hearings began.
Editor's Note: These past few weeks, I've been updating you on a special research project that I've been working on. Well, now, my research is finished and it was well worth the effort. I've pinpointed a tiny company, currently trading for...
Trading volume is going to be thin today, due to the holiday, so I wanted to take this chance to say that I I am thankful for the support of my team and more importantly you the reader. I hope you all had a happy Thanksgiving.
It says to stay away from investing in Chinese stocks during our trade battles with that nation.
It’s a good thing that someone forgot to give Daniel Zhang a copy.
Here’s the thing. While tariffs the U.S. imposed on some Chinese goods have slowed factory output over there, that has hardly filtered down to the nation’s thriving Web sector.
And that’s where Zhang is really shining right now. He’s the CEO of Internet giant Alibaba Group Holding Ltd. (BABA) and just pulled off a remarkable coup.
In the first hour of the firm’s recent Single’s Day shopping bonanza Nov. 11, it brought in $13 billion. No, that’s not a misprint. Alibaba sold more goods in 60 minutes than hundreds of U.S. firms do in a year.
By contrast, that’s roughly 80% of what Amazon.com Inc. (AMZN) pulled in last quarter.
Imagine if all it took to treat a case of cancer was taking out the trash.
Now I want you to imagine that your body could do it all for you.
Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.
Here’s the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as “degraders.”
Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body’s own molecular trash disposal systems.
This is one of the most exciting breakthroughs I’ve come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.
You could forgive drug and biotech executives for having a bad case of target fixation.
After all, they do work in a field that is filled with time-consuming and expensive headaches.
Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.
The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.
With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.
And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.
It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months…